Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (2) Autor Carneiro,R.C.G. (1) Chamone,D.A.F. (1) Dorlhiac-Llacer,P.E. (1) Falcão,R.P. (1) Garcia,A.B. (1) Lima,R.S. Abreu e (1) Maranhão,R.C. (1) Marquezini,M.V. (1) Pintão,M.C. (1) Rego,E.M. (1) Santana,B.A.A. (1) Santos,G.A.S. (1) Scheucher,P.S. (1) Toffoletto,O. (1) Mais... Palavra-chave Acute myelogenous leukemia (2) Acute promyelocytic leukemia (1) Cytotoxicity (1) Daunorubicin (1) Flow cytometry (1) LDE complex (1) Leukemogenesis (1) Low-density lipoprotein (1) RT-PCR (1) Transgenic mice (1) Mais... Tipo do documento Info:eu-repo/semantics/article (1) Info:eu-repo/semantics/other (1) Ano 2006 (1) 2001 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Asynchronous expression of myeloid antigens in leukemic cells in a PML/RARalpha transgenic mouse model BJMBR Santana,B.A.A.; Pintão,M.C.; Lima,R.S. Abreu e; Scheucher,P.S.; Santos,G.A.S.; Garcia,A.B.; Falcão,R.P.; Rego,E.M.. Acute promyelocytic leukemia (APL) is characterized by the expansion of blasts that resemble morphologically promyelocytes and harbor a chromosomal translocation involving the retinoic acid receptor a (RARa) and the promyelocytic leukemia (PML) genes on chromosomes 17 and 15, respectively. The expression of the PML/RARa fusion gene is essential for APL genesis. In fact, transgenic mice (TM) expressing PML/RARa develop a form of leukemia that mimics the hematological findings of human APL. Leukemia is diagnosed after a long latency (approximately 12 months) during which no hematological abnormality is detected in peripheral blood (pre-leukemic phase). In humans, immunophenotypic analysis of APL blasts revealed distinct features; however, the precise... Tipo: Info:eu-repo/semantics/other Palavras-chave: Acute promyelocytic leukemia; Acute myelogenous leukemia; Transgenic mice; Flow cytometry; Leukemogenesis. Ano: 2006 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000500008 In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells BJMBR Dorlhiac-Llacer,P.E.; Marquezini,M.V.; Toffoletto,O.; Carneiro,R.C.G.; Maranhão,R.C.; Chamone,D.A.F.. Acute myelogenous leukemia (AML) blast cells show high-affinity degradation of low-density lipoprotein (LDL), suggesting an increased expression of cellular LDL receptors. LDE is a lipid microemulsion easily synthesized in vitro which is known to mimic the metabolic pathway of LDL. We used LDE as a carrier for daunorubicin and assayed the cytotoxicity of the complex using AML blast cells since RT-PCR analysis showed that AML cells express LDL receptor mRNA. The LDE:daunorubicin complex killed 46.7% of blast cells and 20.2% of normal bone marrow cells (P<0.001; Student t-test). Moreover, this complex destroyed AML blast cells as efficiently as free daunorubicin. Thus, LDE might be a suitable carrier of chemotherapeutic agents targeting these drugs to... Tipo: Info:eu-repo/semantics/article Palavras-chave: Cytotoxicity; Acute myelogenous leukemia; Daunorubicin; Low-density lipoprotein; LDE complex; RT-PCR. Ano: 2001 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001001000004 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco